Table 2.
Multivariate Cox regression model of the risk of death associated with FO measured at baseline across systolic BP categories
| Variables | HR (95% CI) |
|---|---|
| BP<130 FO normal | 1.13 (1.04 to 1.24) |
| BP<130 FO high | 1.51 (1.38 to 1.65) |
| BP=130–160, FO normal | 1.00 (Reference) |
| BP=130–160, FO high | 1.25 (1.16 to 1.36) |
| BP>160, FO normal | 1.05 (0.94 to 1.17) |
| BP>160, FO high | 1.30 (1.19 to 1.42) |
| Sex (1= man) | 0.99 (0.93 to 1.06) |
| Age, per yr | 1.04 (1.03 to 1.04) |
| Height, per cm | 1.00 (1.00 to 1.01) |
| Weight predialysis, per kg | 0.99 (0.99 to 0.99) |
| Preweight − postweight, per kg | 1.04 (1.03 to 1.05) |
| BMI, per kg/m2 | 1.00 (1.00 to 1.00) |
| Treatment time, per min | 1.00 (1.00 to 1.00) |
| Smoking (1= yes) | 1.00 (0.94 to 1.07) |
| Ethnicity (1= white) | 0.75 (0.70 to 0.81) |
| Diabetes | 1.01 (0.95 to 1.07) |
| Coronary artery disease | 1.75 (1.62 to 1.88) |
| Congestive heart failure | 1.70 (1.61 to 1.81) |
| Peripheral vascular disease | 0.86 (0.80 to 0.92) |
| Dementia | 1.28 (1.07 to 1.54) |
| Chronic bronchopulmonary disease | 1.03 (0.94 to 1.12) |
| Paraplegia | 1.03 (0.69 to 1.52) |
| Liver disease | 0.99 (0.90 to 1.10) |
| Connective tissue disorder | 1.23 (0.99 to 1.53) |
| Cerebrovascular disease | 1.13 (1.05 to 1.23) |
| Hb, per g/L | 1.00 (1.00 to 1.00) |
| Albumin, per g/L | 0.94 (0.94 to 0.95) |
| Na, per mmol/L | 0.99 (0.98 to 0.99) |
| Phosphate, per mg/dl | 1.00 (0.99 to 1.02) |
| LDL, per mg/dl | 1.00 (1.00 to 1.00) |
| HDL, per mg/dl | 0.99 (0.99 to 1.00) |
| CRP, per mg/L | 1.03 (1.02 to 1.03) |
| PCRn, per g/kg per day | 0.99 (0.97 to 1.00) |
| Kt/V | 1.00 (1.00 to 1.00) |
| Use of AHT medication (1= yes) | 0.94 (0.89 to 0.99) |
Patients were classified as overhydrated or nonoverhydrated after dividing the cumulative FO by the days of exposure. Such calculation takes back the cumulative estimate to the original scale (single measurement). All comorbidities: 1= yes. BMI, body mass index; Hb, hemoglobin; Na, sodium; CRP, C-reactive protein; PCRn, normalized protein catabolic rate; AHT, antihypertensive treatment.